Luke’s International Hospital (Tokyo), Tadao Akizawa; Showa University Hospital (Tokyo), Eriko Kinugasa; Showa University Yokohama Northern Hospital (Kanagawa), Ashio Yoshimura; Showa University Fujigaoka Hospital (Kanagawa), Hiroshige Ohashi, Hiroshi Oda; Gifu Prefectural General Medical Center (Gifu), Yuzo Watanabe; Kasugai Municipal Hospital (Aichi), Daijo Inaguma, Kei Kurata; Tosei General Hospital (Aichi), Yoshitaka Isaka; Osaka
University Hospital (Osaka), Yoshiharu Tsubakihara; Osaka General Medical Center (Osaka), Masahito Imanishi; Osaka City General Hospital (Osaka), Masaki NVP-BSK805 molecular weight Fukushima; Kurashiki Central Hospital (Okayama), Hideki Hirakata; Fukuoka Red Cross Hospital (Fukuoka), Kazuhito Takeda; Iizuka Hospital (Fukuoka). Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided
the original author(s) and the source are credited. Appendix: Contributors 1. Steering Committee: Akira Hishida (Yaizu City Hospital), Seiichi Matsuo (Nagoya University), Tsuyoshi Watanabe (FG-4592 clinical trial Fukushima Medical University), Yasuo Ohashi (The University of Tokyo), Hirofumi Makino (Okayama University), Tadao Akizawa (Showa University), Kosaku Nitta (Tokyo Women’s Medical University), Enyu Imai (Nagoya University) 2. Data Center: Public Health Research Foundation (Tokyo) 3. Independent Cardiac Function Evaluation Committee:
Kyoichi Mizuno (Nippon Vorinostat nmr Medical School Hospital), Hiroshi Nishimura (The University of Tokyo), Takeo Okada (Osaka Medical Center for Health Science and Promotion), Satoshi Iimuro (The University of Tokyo) 4. Biostatistics Adviser: Yasuo Ohashi (The University of Tokyo) 5. Medical PRKACG Economics Adviser: Takashi Fukuda (The University of Tokyo) 6. Nutrition Evaluation Adviser: Satoshi Sasaki (The University of Tokyo) 7. International Adviser: Harold I Feldman (University of Pennsylvania) 8. General Adviser: Kiyoshi Kurokawa (National Graduate Institute for Policy Study) 9. Sponsor: Kyowa-Hakko-Kirin Co. Ltd. References 1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evidence, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–266. 2. Japanese Society of Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec 31, 2010. 2011. http://docs.jsdt.or.jp/overview/. Accessed 1 Aug 2012. 3. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef 4. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient.